All News

Found 55 articles

• 

  BioSpace Movers & Shakers, November 13

  11/13/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting

  11/10/2020

  Elicio Therapeutics , a next generation immunotherapy company, today announced virtual poster presentations for the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting November 9-14, 2020. The presentations will update progress in two IND-ready programs demonstrating the broad application of Elicio’s Amphiphile Platform, one for a protein subunit vaccine for COVID-19; the other targeting the seven mutations c

• Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CAR T Cells

  9/17/2020

  Elicio Therapeutics, a next generation immuno-oncology company, announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicio’s CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells.

• 

  Biopharma Update on the Novel Coronavirus: August 19

  8/19/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.

• Lymph Node Targeting COVID-19 Vaccine Induces Up To 25-Fold More T Cells Over Benchmark Vaccines and >265-Fold Greater Antibody Levels Than Recovering Patients

  8/19/2020

  Preclinical data from a lymph node targeted COVID-19 vaccine candidate showed potent CD8 and CD4 T Cells in lung tissue and respiratory fluid

• Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002 Mutant KRAS Targeting Mechanism

  4/16/2020

  Elicio Therapeutics, a next generation immuno-oncology company, announced that it has established a collaboration with the National Cancer Institute to characterize T cell responses to ELI-002 in animals.

• Elicio Therapeutics to Discuss Novel Lymph Node Vaccine Targeting Seven Key mKRAS Mutations at RAS - Targeted Drug Discovery Summit in Vienna, Austria

  2/19/2020

  Elicio Therapeutics, a next generation immuno-oncology company, today announced Peter DeMuth, PhD., Elicio Vice President of Research, will present “Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses,” at the upcoming RAS-Targeted Drug Discovery Summit in Vienna, Austria, from February 25 to 27, 2020.

• 

  Clinical Catch-Up: February 10-14

  2/17/2020

  It was a very busy week for clinical trial news. Here’s a look.

• Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002

  2/11/2020

  Signatera test used for patient selection and monitoring to accelerate molecular proof of concept   [11-February-2020]   CAMBRIDGE , Mass. and SAN CARLOS, Calif. , Feb. 11, 2020 /PRNewswire/ --  Elicio Therapeutics , a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collabora

• Physician-Scientist Christopher Haqq M.D., Ph.D. Joins Elicio Therapeutics as Research and Development Head

  10/23/2019

  Elicio Therapeutics, a next generation immuno-oncology company, announced today that Christopher Haqq M.D., Ph.D. has joined Elicio as Executive Vice President, Head of Research and Development, and Chief Medical Officer.

• Elicio Therapeutics Completes $33 Million Series B Financing

  10/2/2019

  Elicio Therapeutics, a next generation immuno-oncology company, announced today that it has closed its $33 million Series B financing. Proceeds from the financing will be used to advance Elicio’s pipeline of novel lymph node targeted immuno-therapies, including ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS). ELI-002 targets all seven KRAS mutations that drive 99% of all mKRAS-driven cancers, estimated to be 25% of all human solid tumors.

• Elicio Therapeutics Presents In Vivo Data for a Universal Amphiphile Vaccine Targeting KRAS-Driven Cancers

  8/7/2019

  Phase One patient data from a potential therapy targeting a single KRAS mutation, formerly considered “undruggable,” has been introduced in 2019.

• Elicio Therapeutics Co-founder, Darrell Irvine, Co-authors Research Published in Science Demonstrating Novel AMP-CAR-T Approach to Enhance CAR-T Function in Solid Tumor Cancers

  7/11/2019

  Elicio Therapeutics, today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response.

• Windtree Therapeutics Appoints Daniel Geffken to Board of Directors

  4/30/2019

  Windtree Therapeutics, Inc., announced it has appointed Daniel Geffken to the Company's Board of Directors, effective April 24, 2019.

• Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancers

  3/27/2019

  Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, launched today and announced the appointment of Robert Connelly as CEO.